logo

Caladrius Biosciences, Inc. (CLBS)



Trade CLBS now with
  Date
  Headline
3/8/2021 8:12:08 AM Caladrius Biosciences Reports Orphan Drug Designation For CLBS12 For Treatment Of Buerger’s Disease
11/2/2020 8:38:19 AM Caladrius Biosciences Appoints Anne Whitaker To Board
6/2/2020 8:10:45 AM Caladrius To Present On CLBS119 For COVID-19 Induced Lung Damage At BioNJ COVID-19 Rapid Fire Research Showcase
5/26/2020 8:05:11 AM Caladrius Biosciences Announces $4.3 Mln Direct Offering
4/22/2020 8:06:00 AM Caladrius To Get $10.9 Mln Of Non-Dilutive Capital Through NJEDA' Technology Business Tax Certificate Transfer Program
7/15/2019 8:40:44 AM Caladrius Biosciences Says EMA Grants Advanced Therapy Medicinal Product Classification For CLBS12
6/4/2019 8:38:17 AM Caladrius Biosciences Completes Enrollment In Phase 2 ESCaPE-CMD Trial For Coronary Microvascular Dysfunction
5/14/2019 6:43:19 AM WBB Securities Starts Caladrius Biosciences, Inc. (CLBS) At Speculative Buy With $6.75 Price Target
11/8/2018 8:32:16 AM Caladrius Biosciences Appoints Cynthia Schwalm To Board